Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 8 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

8Total

P 1 (3)

P 2 (2)

P 3 (1)

P 4 (2)

Trial Status

Completed3

Recruiting3

Active Not Recruiting1

Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07594314Phase 2Recruiting

Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)

NCT07594301Phase 2Recruiting

Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)

NCT05512910Phase 4Active Not Recruiting

Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)

NCT04210713Phase 1Completed

Neuroimmune Dysfunction in Alcohol Use Disorder

NCT05474950Phase 1UnknownPrimary

Minocycline Treatment for Cystoid Macular Edema

NCT05474729Phase 1RecruitingPrimary

Minocycline for Chronic Autoimmune Uveitis

NCT00146809Phase 3Completed

Study About Efficacy and Safety to Treat Multi-System-Atrophy

NCT00409747Phase 4Completed

Minocycline to Treat Childhood Regressive Autism

Showing all 8 trials

Minocycline